209 related articles for article (PubMed ID: 35216175)
41. Molecular determinants of the interaction between glioblastoma CD133
Shevchenko V; Arnotskaya N; Pak O; Sharma A; Sharma HS; Khotimchenko Y; Bryukhovetskiy A; Bryukhovetskiy I
Int Rev Neurobiol; 2020; 151():155-169. PubMed ID: 32448605
[TBL] [Abstract][Full Text] [Related]
42. Extracellular Vesicles from Neurosurgical Aspirates Identifies Chaperonin Containing TCP1 Subunit 6A as a Potential Glioblastoma Biomarker with Prognostic Significance.
Hallal S; Russell BP; Wei H; Lee MYT; Toon CW; Sy J; Shivalingam B; Buckland ME; Kaufman KL
Proteomics; 2019 Jan; 19(1-2):e1800157. PubMed ID: 30451371
[TBL] [Abstract][Full Text] [Related]
43. Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy.
Rose M; Cardon T; Aboulouard S; Hajjaji N; Kobeissy F; Duhamel M; Fournier I; Salzet M
Front Immunol; 2021; 12():746168. PubMed ID: 34646273
[TBL] [Abstract][Full Text] [Related]
44. Role of Tumor-Derived Extracellular Vesicles in Glioblastoma.
Chen Y; Jin Y; Wu N
Cells; 2021 Feb; 10(3):. PubMed ID: 33670924
[TBL] [Abstract][Full Text] [Related]
45. Glioblastoma Extracellular Vesicle-Specific Peptides Inhibit EV-Induced Neuronal Cytotoxicity.
Zhou W; Craft J; Ojemann A; Bergen L; Graner A; Gonzales A; He Q; Kopper T; Smith M; Graner MW; Yu X
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806205
[TBL] [Abstract][Full Text] [Related]
46. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
47. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy.
Wang J; Liu Y; Liu F; Gan S; Roy S; Hasan I; Zhang B; Guo B
Nanoscale; 2023 Jul; 15(26):10904-10938. PubMed ID: 37337814
[TBL] [Abstract][Full Text] [Related]
48. FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.
Maachani UB; Shankavaram U; Kramp T; Tofilon PJ; Camphausen K; Tandle AT
Oncotarget; 2016 Nov; 7(47):77365-77377. PubMed ID: 27764801
[TBL] [Abstract][Full Text] [Related]
49. Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D Culture.
D'Souza RCJ; Offenhäuser C; Straube J; Baumgartner U; Kordowski A; Li Y; Stringer BW; Alexander H; Lwin Z; Inglis PL; Jeffree RL; Johns TG; Boyd AW; Day BW
Cells; 2020 Jan; 9(2):. PubMed ID: 31973233
[TBL] [Abstract][Full Text] [Related]
50. Multi-Omics Data Integration and Mapping of Altered Kinases to Pathways Reveal Gonadotropin Hormone Signaling in Glioblastoma.
Jayaram S; Gupta MK; Raju R; Gautam P; Sirdeshmukh R
OMICS; 2016 Dec; 20(12):736-746. PubMed ID: 27930095
[TBL] [Abstract][Full Text] [Related]
51. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Nawaz Z; Patil V; Paul Y; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Mol Cancer; 2016 Nov; 15(1):74. PubMed ID: 27871300
[TBL] [Abstract][Full Text] [Related]
52. Global extracellular vesicle proteomic signature defines U87-MG glioma cell hypoxic status with potential implications for non-invasive diagnostics.
Indira Chandran V; Welinder C; Gonçalves de Oliveira K; Cerezo-Magaña M; Månsson AS; Johansson MC; Marko-Varga G; Belting M
J Neurooncol; 2019 Sep; 144(3):477-488. PubMed ID: 31414377
[TBL] [Abstract][Full Text] [Related]
53. ExRNA in Biofluids as Biomarkers for Brain Tumors.
Rennert RC; Hochberg FH; Carter BS
Cell Mol Neurobiol; 2016 Apr; 36(3):353-60. PubMed ID: 26993514
[TBL] [Abstract][Full Text] [Related]
54. Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype.
Oushy S; Hellwinkel JE; Wang M; Nguyen GJ; Gunaydin D; Harland TA; Anchordoquy TJ; Graner MW
Philos Trans R Soc Lond B Biol Sci; 2018 Jan; 373(1737):. PubMed ID: 29158308
[TBL] [Abstract][Full Text] [Related]
55. High-capacity glycolytic and mitochondrial oxidative metabolisms mediate the growth ability of glioblastoma.
Kim J; Han J; Jang Y; Kim SJ; Lee MJ; Ryu MJ; Kweon GR; Heo JY
Int J Oncol; 2015 Sep; 47(3):1009-16. PubMed ID: 26202438
[TBL] [Abstract][Full Text] [Related]
56. Tracking intratumoral heterogeneity in glioblastoma via regularized classification of single-cell RNA-Seq data.
Lopes MB; Vinga S
BMC Bioinformatics; 2020 Feb; 21(1):59. PubMed ID: 32070274
[TBL] [Abstract][Full Text] [Related]
57. Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.
Osti D; Del Bene M; Rappa G; Santos M; Matafora V; Richichi C; Faletti S; Beznoussenko GV; Mironov A; Bachi A; Fornasari L; Bongetta D; Gaetani P; DiMeco F; Lorico A; Pelicci G
Clin Cancer Res; 2019 Jan; 25(1):266-276. PubMed ID: 30287549
[TBL] [Abstract][Full Text] [Related]
58. Secreted Glioblastoma Nanovesicles Contain Intracellular Signaling Proteins and Active Ras Incorporated in a Farnesylation-dependent Manner.
Luhtala N; Aslanian A; Yates JR; Hunter T
J Biol Chem; 2017 Jan; 292(2):611-628. PubMed ID: 27909058
[TBL] [Abstract][Full Text] [Related]
59. Expression of
Korbecki J; Kojder K; Jeżewski D; Simińska D; Tarnowski M; Kopytko P; Safranow K; Gutowska I; Goschorska M; Kolasa-Wołosiuk A; Wiszniewska B; Chlubek D; Baranowska-Bosiacka I
Biomolecules; 2020 May; 10(5):. PubMed ID: 32392704
[TBL] [Abstract][Full Text] [Related]
60. Bioinformatics and machine learning methodologies to identify the effects of central nervous system disorders on glioblastoma progression.
Rahman MH; Rana HK; Peng S; Hu X; Chen C; Quinn JMW; Moni MA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33406529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
